Polatuzumab vedotin (Polivy) — Clinical FAQs

Question 1

What is Polatuzumab vedotin FDA-approved to treat?

Accepted Answer

Polatuzumab vedotin is FDA-approved for the following oncology indications: 1. Previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma with MYC and BCL2 rearrangements, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) (April 2023; POLARIX trial) 2. Relapsed or refractory DLBCL after ≥2 prior therapies, in combination with bendamustine and rituximab (June 2019, accelerated approval; GO29365 trial).

Question 2

How does Polatuzumab vedotin work (mechanism of action)?

Accepted Answer

Polatuzumab vedotin is an antibody-drug conjugate (ADC) consisting of a humanized anti-CD79b IgG1 monoclonal antibody conjugated via a protease-cleavable maleimidocaproyl valine-citrulline linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. CD79b is a component of the B-cell receptor signaling complex expressed on B cells and most B-cell lymphomas. Upon binding CD79b, the ADC is internalized and the linker cleaved by lysosomal proteases, releasing MMAE intracellularly. Free MMAE inhibits tubulin polymerization, causing G2/M cell cycle arrest and apoptosis. Bystander killing of antigen-negative neighboring cells is possible due to MMAE's membrane permeability.

Question 3

How is Polatuzumab vedotin administered?

Accepted Answer

Polatuzumab vedotin is administered Intravenous (IV). Administered as an IV infusion.

Question 4

What are the most common side effects of Polatuzumab vedotin?

Accepted Answer

The most commonly reported side effects of Polatuzumab vedotin (≥10% incidence) include: Peripheral neuropathy (~43–48%, sensory and motor), Fatigue (~37%), Nausea (~32%), Diarrhea (~30%), Neutropenia (~64%) and others (12 total). Consult your oncologist for complete prescribing information.

Question 5

Does Polatuzumab vedotin have a black box warning?

Accepted Answer

Yes. Polatuzumab vedotin carries FDA black box warning(s) regarding: 1. Peripheral neuropathy: cumulative sensory/motor neuropathy; assess prior to each dose and reduce dose or discontinue based on severity 2. Infusion-related reactions including anaphylaxis 3. Progressive multifocal leukoencephalopathy (PML): JC virus-related fatal and life-threatening PML reported; withhold at first signs and discontinue if confirmed

Question 6

Is Polatuzumab vedotin safe during pregnancy?

Accepted Answer

Polatuzumab vedotin pregnancy safety: Pregnancy Category D equivalent (post-PLLR). MMAE can cause embryo-fetal harm based on mechanism of action (microtubule disruption). Women of reproductive potential should use effective contraception during and for 3 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during and for 5 months after the last dose. Breastfeeding is contraindicated during and for at least 3 months after the last dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

polatuzumab vedotin — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms